Abstract
Autologous stem cell transplantation appears to enhance outcome in multiple myeloma patients. To improve upon these results, various groups have utilized tandem autografts, as well as used reduced-conditioning allogeneic stem cell transplantation. These two approaches, discussed herein, have been promising. Inherent patient selection, however, appears to play a role and much of the data have not yet been subjected to peer-review scrutiny. At present, these strategies remain investigational and cannot be considered the standard-of-care for multiple myeloma patients.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Graft vs Host Disease / etiology
-
Hematopoietic Stem Cell Mobilization / methods
-
Hematopoietic Stem Cell Transplantation / methods*
-
Humans
-
Middle Aged
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / mortality
-
Multiple Myeloma / therapy*
-
Prognosis
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Remission Induction
-
Risk Factors
-
Transplantation Conditioning / adverse effects
-
Transplantation Conditioning / methods
-
Transplantation, Autologous
-
Transplantation, Homologous
-
Treatment Outcome